• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Dec 5, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 29, 2023
    Insmed To Present at the Nasdaq 49th Investor Conference
  • Nov 8, 2023
    Insmed To Present at Two November Conferences
  • Nov 3, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 2, 2023
    Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
  • Oct 26, 2023
    Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
  • Oct 26, 2023
    Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
  • Oct 24, 2023
    Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
  • Oct 12, 2023
    Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
  • Oct 6, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 26, 2023
    Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
  • Sep 8, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 6, 2023
    Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
  • Sep 5, 2023
    INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
  • Aug 4, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 3, 2023
    Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
  • Jul 20, 2023
    Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
  • Jul 7, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 7, 2023
    Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
  • Jun 6, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 22, 2023
    Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
  • May 8, 2023
    Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
  • May 5, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 4, 2023
    Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
  • Apr 24, 2023
    Insmed to Host Investor and Analyst Event on May 8, 2023
  • Apr 20, 2023
    Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
  • Apr 6, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 31, 2023
    Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
  • Mar 24, 2023
    Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
  • Mar 3, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 1, 2023
    Insmed To Present at Two March Conferences
  • Feb 23, 2023
    Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
  • Feb 9, 2023
    Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
  • Feb 7, 2023
    Insmed To Present at the SVB Securities Global Biopharma Conference
  • Feb 3, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 20, 2023
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 6, 2023
    Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
  • Jan 3, 2023
    Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
  • Dec 6, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 30, 2022
    Insmed To Present at the Nasdaq 47th Investor Conference
  • Nov 4, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 1, 2022
    Insmed To Present at Three November Conferences
  • Oct 27, 2022
    Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
  • Oct 27, 2022
    Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
  • Oct 19, 2022
    Insmed Announces Strategic Financings Totaling $775 Million
  • Oct 13, 2022
    Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
  • Oct 7, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Oct 6, 2022
    Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
  • Sep 7, 2022
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 6, 2022
    Insmed To Present at Two September Conferences
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy